Partnership with Bio NTech for COVID-19 vaccine
GPTKB entity
Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:collaboration
|
| gptkbp:addresses |
pandemic challenges
|
| gptkbp:aims_to |
reduce transmission
achieve herd immunity develop a vaccine |
| gptkbp:contributed_to |
global vaccination efforts
|
| gptkbp:established |
gptkb:2020
|
| gptkbp:has |
multiple phases
multiple stakeholders ongoing research global impact significant funding high efficacy |
| https://www.w3.org/2000/01/rdf-schema#label |
Partnership with Bio NTech for COVID-19 vaccine
|
| gptkbp:includes |
gptkb:Pfizer
research funding |
| gptkbp:increased |
vaccine availability
|
| gptkbp:involves |
gptkb:vaccine
gptkb:Bio_NTech gptkb:supply_chain_management clinical research regulatory approvals manufacturing scale-up |
| gptkbp:is |
recognized globally
widely distributed a collaborative effort a public-private partnership a public health initiative a strategic alliance part of vaccination campaigns a partnership for innovation a collaborative research initiative a key development in vaccine technology a key player in vaccine development a milestone in public health a model for future collaborations a partnership for global health a response to COVID-19 pandemic a response to emerging infectious diseases a response to global health crisis a response to vaccine hesitancy a significant achievement in science |
| gptkbp:is_enhanced_by |
public health response
|
| gptkbp:is_focused_on |
m RNA technology
|
| gptkbp:is_supported_by |
gptkb:governments
|
| gptkbp:is_targeted_at |
gptkb:SARS-Co_V-2
|
| gptkbp:led_to |
clinical trials
|
| gptkbp:received |
emergency use authorization
|
| gptkbp:resulted_in |
gptkb:Comirnaty
|
| gptkbp:utilizes |
cold chain logistics
|
| gptkbp:bfsParent |
gptkb:Pfizer
|
| gptkbp:bfsLayer |
4
|